Cart
sales@molnova.com
BIBF0775
CAS No. 334951-90-5
BIBF0775( —— )
Catalog No. M20053 CAS No. 334951-90-5
BIBF0775 is a selective TGFβ type I receptor (Alk5) inhibitor (IC50: 34 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 132 | In Stock |
|
| 10MG | 205 | In Stock |
|
| 25MG | 340 | In Stock |
|
| 50MG | 478 | In Stock |
|
| 100MG | 691 | In Stock |
|
| 500MG | 1422 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBIBF0775
-
NoteResearch use only, not for human use.
-
Brief DescriptionBIBF0775 is a selective TGFβ type I receptor (Alk5) inhibitor (IC50: 34 nM).
-
DescriptionBIBF0775 is a selective TGFβ type I receptor (Alk5) inhibitor (IC50: 34 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorTGFβR1(ALK5)|Alk5
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number334951-90-5
-
Formula Weight494.64
-
Molecular FormulaC31H34N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: 60 mg/mL
-
SMILESCCN(C)C(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(CN3CCCCC3)cc2)c2ccccc2)c1
-
Chemical Name(3Z)-N-Ethyl-23-dihydro-N-methyl-2-oxo-3-[phenyl[[4-(1-piperidinylmethyl)phenyl]amino]methylene]-1H-indole-6-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Roth GJ et al. Design synthesis and evaluation of indolinones as inhibitors of the transforming growth factor β receptor I (TGFβRI). J Med Chem. 2010 Oct 28;53(20):7287-95.
molnova catalog
related products
-
H-Arg-4MβNA
H-Arg-4MβNA (H-Arg-4MbNA) is a peptide that serves as a substrate for cathepsin H. The enzyme activity is often detected in gel electrophoresis.
-
Gossypetin 3-sophoro...
The herbs of Abelmoschus manihot.
-
Examorelin
Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?
